TY - JOUR
T1 - Magnetic Seizure Therapy
T2 - an Evolution of Convulsive Therapy
AU - Martits-Chalangari, Katalin
AU - Milton, Alexis
AU - Husain, Mustafa M.
N1 - Funding Information:
Dr. Katalin Martits-Chalangari and Alexis Milton declare that they have no conflict of interest. Dr. Mustafa M. Husain declares grant support from NIH, NIMH, NIDA, NINDS, NIA, NARSD, Stanley Medical Foundation, Cyberonics, Neuronetics (past), St. Jude Medical (ANS), MagStim (equip only), Brainsway, NeoSync, Alkermes, Assurex, and Avanir. He reports research consulting for Allergen and AtheaDx.
Publisher Copyright:
© 2016, Springer International Publishing AG.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Purpose of Review: Treatment-resistant depression (TRD) affects a significant subset of depressed patients. It is estimated that about 30 % of patients with major depressive disorder do not respond to standard treatments. For these patients, electroconvulsive therapy (ECT) remains the most effective treatment despite being limited by its side effects. Modifications to ECT parameters have suggested that it may be possible to separate the therapeutic effects of convulsive therapy from the production of side effects. Recent Findings: Magnetic seizure therapy (MST), which uses electromagnetic induction to induce a seizure, is an alternative, experimental convulsive treatment for major depression. Seizures induced by MST are more focal than those produced by ECT, thereby offering greater control over the induced electric field. Most importantly, it offers the potential to provide antidepressant effect without cognitive side effects. Recent findings have further shown the effectiveness of MST and compared cognitive and metabolic side effects to ECT. Summary: This article reviews the current literature for clinical studies on MST. While initial results are promising, future work is needed to compare MST efficacy with other antidepressant treatments.
AB - Purpose of Review: Treatment-resistant depression (TRD) affects a significant subset of depressed patients. It is estimated that about 30 % of patients with major depressive disorder do not respond to standard treatments. For these patients, electroconvulsive therapy (ECT) remains the most effective treatment despite being limited by its side effects. Modifications to ECT parameters have suggested that it may be possible to separate the therapeutic effects of convulsive therapy from the production of side effects. Recent Findings: Magnetic seizure therapy (MST), which uses electromagnetic induction to induce a seizure, is an alternative, experimental convulsive treatment for major depression. Seizures induced by MST are more focal than those produced by ECT, thereby offering greater control over the induced electric field. Most importantly, it offers the potential to provide antidepressant effect without cognitive side effects. Recent findings have further shown the effectiveness of MST and compared cognitive and metabolic side effects to ECT. Summary: This article reviews the current literature for clinical studies on MST. While initial results are promising, future work is needed to compare MST efficacy with other antidepressant treatments.
KW - Cognition
KW - ECT
KW - Electroconvulsive therapy
KW - MST
KW - Magnetic seizure therapy
KW - Major depression
KW - Neuromodulation
KW - TRD
KW - Treatment-resistant depression
UR - http://www.scopus.com/inward/record.url?scp=85090084953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090084953&partnerID=8YFLogxK
U2 - 10.1007/s40473-016-0094-1
DO - 10.1007/s40473-016-0094-1
M3 - Review article
AN - SCOPUS:85090084953
SN - 2196-2979
VL - 3
SP - 376
EP - 380
JO - Current Behavioral Neuroscience Reports
JF - Current Behavioral Neuroscience Reports
IS - 4
ER -